1 Prohibited Substances ANABOLIC AGENTS 1 Anabolic Androgenic Steroids (AAS) • The sub-division of anabolic androgenic steroids (AAS) into ‘a. exogenous’ and ‘b. endogenous’ was removed and all AAS were joined into one class. The prohibited substances in S1 have not changed but two additional examples (methylclostebol and 1-epiandrosterone) were included. This change was made to reflect the fact that all anabolic agents when administered exogenously are prohibited and harmonizes the presentation of S1 with other classes of the List which do not distinguish endogenous from exogenous. The determination of the substances’ origin (i.e. whether they are of endogenous or exogenous nature) is, as before, regulated in the corresponding technical document TD2019IRMS or any other applicable technical document (e.g. TD2019NA) or Technical Letter. 2 Other Anabolic Agents • LGD-4033 is now also listed by another commonly used name, ligandrol. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS • After re-evaluation, argon was removed from the Prohibited List because it is considered to no longer meet the criteria for inclusion. • TGF-ß inhibitors: The word “signalling” was added to better reflect the predominant mechanism of action of the listed substances. It now reads “TGF-ß signalling inhibitors”. S1 S2 HORMONE AND METABOLIC MODULATORS • Bazedoxifene and ospemifene were added as additional examples of selective estrogen receptor modulators. Prohibited Methods CHEMICAL AND PHYSICAL MANIPULATION • The wording was changed to clarify that the context of protease prohibition refers only to the tampering of samples. Topical and systemic therapeutic use of proteases are not prohibited. GENE AND CELL DOPING • Classes M3.1 and M3.2 were combined, since the effects of gene doping on gene expression can be produced by technologies other than gene editing. • “Transcriptional, post-transcriptional or epigenetic regulation of gene expression” were changed to “gene expression by any mechanism” to encompass a wide range of mechanisms without exhaustively listing all steps at which gene expression may be altered. • “Gene silencing” and “gene transfer” were added as further examples of gene doping methods. • “Polymers of” was removed to reflect standard scientific terminology for nucleic acids. • Regarding stem cells, reiterating the statement in the Prohibited List Q & A, non-transformed stem cells, used alone (with no growth factors or other hormones added) for healing injuries are not prohibited, as long as they return the function of the affected area to normal and do not enhance it. S4 M2 M3 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES 2020 PROHIBITED LIST Substances and methods prohibited at all times (In- and Out-of-Competition) 2 Substances and Methods Prohibited In-Competition STIMULANTS • Octodrine (1,5-dimethylhexylamine) was added as an example of Specified Stimulants. This substance was recently found in some dietary supplements. • It is clarified that administration of imidazole derivatives is not prohibited when used by dermatological, nasal and ophthalmological routes. NARCOTICS • For clarity it was stated that all optical isomers are prohibited. This clarifies the prohibited status of optical isomers such as levomethadone. CANNABINOIDS • The wording of S8 Cannabinoids was updated for greater clarity. The substances that are prohibited were not changed. All natural and synthetic cannabinoids are prohibited including any preparation from cannabis or any synthetic cannabinoid. Natural ∆9-tetrahydrocannabinol (THC) and synthetic THC (e.g. dronabinol) are prohibited. All synthetic cannabinoids that mimic the effects of THC are prohibited. • Cannabidiol (CBD) is not prohibited. However, athletes should be aware that some CBD products extracted from cannabis plants may also contain THC that could result in a positive test for a prohibited cannabinoid. S6 S7 S6 Monitoring Program • Ecdysterone was included in the Monitoring Program to assess patterns and prevalence of misuse. While other ecdysteroids exist, most data (especially concerning effects on athletic performance) and stakeholder comments centre around ecdysterone, and consequently it was added to the Monitoring Program of 2020. * For further information on previous modifications and clarifications please consult the Prohibited List Q & A at www.wada-ama.org/en/questions-answers/prohibited-list- qa

1 Prohibited Substances ANABOLIC AGENTS 1 Anabolic Androgenic Steroids (AAS) • The sub-division of anabolic androgenic steroids (AAS) into ‘a. exogenous’ and ‘b. endogenous’ was removed and all AAS were joined into one class. The prohibited substances in S1 have not changed but two additional examples (methylclostebol and 1-epiandrosterone) were included. This change was made to reflect the fact that all anabolic agents when administered exogenously are prohibited and harmonizes the presentation of S1 with other classes of the List which do not distinguish endogenous from exogenous. The determination of the substances’ origin (i.e. whether they are of endogenous or exogenous nature) is, as before, regulated in the corresponding technical document TD2019IRMS or any other applicable technical document (e.g. TD2019NA) or Technical Letter. 2 Other Anabolic Agents • LGD-4033 is now also listed by another commonly used name, ligandrol. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS • After re-evaluation, argon was removed from the Prohibited List because it is considered to no longer meet the criteria for inclusion. • TGF-ß inhibitors: The word “signalling” was added to better reflect the predominant mechanism of action of the listed substances. It now reads “TGF-ß signalling inhibitors”. S1 S2 HORMONE AND METABOLIC MODULATORS • Bazedoxifene and ospemifene were added as additional examples of selective estrogen receptor modulators. Prohibited Methods CHEMICAL AND PHYSICAL MANIPULATION • The wording was changed to clarify that the context of protease prohibition refers only to the tampering of samples. Topical and systemic therapeutic use of proteases are not prohibited. GENE AND CELL DOPING • Classes M3.1 and M3.2 were combined, since the effects of gene doping on gene expression can be produced by technologies other than gene editing. • “Transcriptional, post-transcriptional or epigenetic regulation of gene expression” were changed to “gene expression by any mechanism” to encompass a wide range of mechanisms without exhaustively listing all steps at which gene expression may be altered. • “Gene silencing” and “gene transfer” were added as further examples of gene doping methods. • “Polymers of” was removed to reflect standard scientific terminology for nucleic acids. • Regarding stem cells, reiterating the statement in the Prohibited List Q & A, non-transformed stem cells, used alone (with no growth factors or other hormones added) for healing injuries are not prohibited, as long as they return the function of the affected area to normal and do not enhance it. S4 M2 M3 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES 2020 PROHIBITED LIST Substances and methods prohibited at all times (In- and Out-of-Competition) 2 Substances and Methods Prohibited In-Competition STIMULANTS • Octodrine (1,5-dimethylhexylamine) was added as an example of Specified Stimulants. This substance was recently found in some dietary supplements. • It is clarified that administration of imidazole derivatives is not prohibited when used by dermatological, nasal and ophthalmological routes. NARCOTICS • For clarity it was stated that all optical isomers are prohibited. This clarifies the prohibited status of optical isomers such as levomethadone. CANNABINOIDS • The wording of S8 Cannabinoids was updated for greater clarity. The substances that are prohibited were not changed. All natural and synthetic cannabinoids are prohibited including any preparation from cannabis or any synthetic cannabinoid. Natural ∆9-tetrahydrocannabinol (THC) and synthetic THC (e.g. dronabinol) are prohibited. All synthetic cannabinoids that mimic the effects of THC are prohibited. • Cannabidiol (CBD) is not prohibited. However, athletes should be aware that some CBD products extracted from cannabis plants may also contain THC that could result in a positive test for a prohibited cannabinoid. S6 S7 S6 Monitoring Program • Ecdysterone was included in the Monitoring Program to assess patterns and prevalence of misuse. While other ecdysteroids exist, most data (especially concerning effects on athletic performance) and stakeholder comments centre around ecdysterone, and consequently it was added to the Monitoring Program of 2020. * For further information on previous modifications and clarifications please consult the Prohibited List Q & A at www.wada-ama.org/en/questions-answers/prohibited-list- qa

THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2020 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2020 2 IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. ANABOLIC AGENTS Anabolic agents are prohibited. 1. ANABOLIC ANDROGENIC STEROIDS (AAS) when administered exogenously, including but not limited to: 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one); 1-Epiandrosterone (3β-hydroxy-5α-androst-1-ene-17-one); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Androstenediol (androst-4-ene-3β,17β-diol); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3- one); 5-Androstenedione (androst-5-ene-3,17-dione); 7α-hydroxy-DHEA; 7β-hydroxy-DHEA; 7-Keto-DHEA; 19-Norandrostenediol (estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α- androstan-3-one); Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Bolasterone; Boldenone; Boldione (androsta-1,4-diene-3,17-dione); S0 S1 Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-androst- 2-en-17β-ol and 17α-methyl-5α-androst-3-en-17β-ol); Drostanolone; Epiandrosterone (3β-hydroxy-5α-androstan-17-one); Epi-dihydrotestosterone (17β-hydroxy-5β-androstan-3- one); Epitestosterone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α- androstan-17β-ol); Gestrinone; Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- 3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- androstan-3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- androst-1-en-3-one); Methylclostebol; Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17α- methylestra-4,9,11-trien-3-one); Mibolerone; Nandrolone (19-nortestosterone); Norboletone; 3 Norclostebol (4-chloro-17β-ol-estr-4-en-3-one); Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H- pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Testosterone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α- pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). 2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, selective androgen receptor modulators [SARMs, e.g. andarine, LGD-4033 (ligandrol), enobosarm (ostarine) and RAD140], tibolone, zeranol and zilpaterol. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoietins (EPO) and agents affecting erythropoiesis, including, but not limited to: 1.1 Erythropoietin-Receptor Agonists, e.g. Darbepoetins (dEPO); Erythropoietins (EPO); EPO based constructs [e.g. EPO-Fc, methoxy polyeth- ylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). 1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. Cobalt; Daprodustat (GSK1278863); Molidustat (BAY 85-3934); Roxadustat (FG-4592); Vadadustat (AKB-6548); Xenon. 1.3 GATA inhibitors, e.g. K-11706. 1.4 TGF-beta (TGF-β) signalling inhibitors, e.g. Luspatercept; Sotatercept. 1.5 Innate repair receptor agonists, e.g. Asialo EPO; Carbamylated EPO (CEPO). S2 4 2. Peptide Hormones and their Releasing Factors, 2.1 Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors in males, e.g. Buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin; 2.2 Corticotrophins and their releasing factors, e.g. Corticorelin; 2.3 Growth Hormone (GH), its fragments and releasing factors, including, but not limited to: Growth Hormone fragments, e.g. AOD-9604 and hGH 176-191; Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. Lenomorelin (ghrelin) and its mimetics, e.g. Anamorelin, ipamorelin, macimorelin and tabimorelin; GH-Releasing Peptides (GHRPs), e.g. Alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin). 3. Growth Factors and Growth Factor Modulators, including, but not limited to: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Thymosin-β4 and its derivatives e.g. TB-500; Vascular-Endothelial Growth Factor (VEGF); and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/ degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. BETA-2 AGONISTS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: Fenoterol; Formoterol; Higenamine; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Salmeterol; Terbutaline; Tretoquinol (trimetoquinol); Tulobuterol; Vilanterol. Except: • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. S3 5 HORMONE AND METABOLIC MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 2-Androstenol (5α-androst-2-en-17-ol); 2-Androstenone (5α-androst-2-en-17-one); 3-Androstenol (5α-androst-3-en-17-ol); 3-Androstenone (5α-androst-3-en-17-one); 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Bazedoxifene; Ospemifene; Raloxifene; Tamoxifen; Toremifene. 3. Other anti-estrogenic substances including, but not limited to: Clomifene; Cyclofenil; Fulvestrant. 4. Agents preventing activin receptor IIB activation including, but not limited, to: Activin A-neutralizing antibodies; Activin receptor IIB competitors such as: Decoy activin receptors (e.g. ACE-031); Anti-activin receptor IIB antibodies (e.g. Bimagrumab); Myostatin inhibitors such as: Agents reducing or ablating myostatin expression; Myostatin-binding proteins (e.g. Follistatin, myostatin propeptide); Myostatin-neutralizing antibodies (e.g. Domagrozumab, S4 landogrozumab, stamulumab). 5. Metabolic modulators: 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl) phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516); 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. Bendroflu- methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. Tolvaptan. Except: • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. Dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. S5 6 PROHIBITED METHODS MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. Haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Sample substitution and/or adulteration, e.g. Addition of proteases to Sample. 2. Intravenous infusions and/or injections of more than a total of 100 mL per 12 hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M1 M2 GENE AND CELL DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies. 3. The use of normal or genetically modified cells. M3 7 IN ADDITION TO THE CLASSES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CLASSES ARE PROHIBITED IN-COMPETITION: SUBSTANCES & METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES STIMULANTS All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include: a: Non-Specified Stimulants: Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-methylamfetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane. A stimulant not expressly listed in this section is a Specified Substance. S6 b: Specified Stimulants: Including, but not limited to: 3-Methylhexan-2-amine (1,2-dimethylpentylamine); 4-Methylhexan-2-amine (methylhexaneamine); 4-Methylpentan-2-amine (1,3-dimethylbutylamine); 5-Methylhexan-2-amine (1,4-dimethylpentylamine); Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone, methedrone, and α - pyrrolidinovalerophenone; Dimetamfetamine (dimethylamphetamine); Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***; Methylphenidate; Nikethamide; Norfenefrine; Octodrine (1,5-dimethylhexylamine); Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; 8 Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). Except: • Clonidine; • Imidazole derivatives for dermatological, nasal or ophthalmic use and those stimulants included in the 2020 Monitoring Program*. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2020 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter. NARCOTICS The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited: Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Nicomorphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine. CANNABINOIDS All natural and synthetic cannabinoids are prohibited, e.g. • In cannabis (hashish, marijuana) and cannabis products • Natural and synthetic tetrahydrocannabinols (THCs) • Synthetic cannabinoids that mimic the effects of THC Except: • Cannabidiol. GLUCOCORTICOIDS All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. Including but not limited to: Betamethasone; Budesonide; Cortisone; Deflazacort; Dexamethasone; Fluticasone; Hydrocortisone; Methylprednisolone; Prednisolone; Prednisone; Triamcinolone. S7 S8 S9 9 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS BETA-BLOCKERS Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated. • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea. *Also prohibited Out-of-Competition Including, but not limited to: Acebutolol; Labetalol; Alprenolol; Metipranolol; Atenolol; Metoprolol; Betaxolol; Nadolol; Bisoprolol; Oxprenolol; Bunolol; Pindolol; Carteolol; Propranolol; Carvedilol; Sotalol; Celiprolol; Timolol. Esmolol; P1 www.wada-ama.org

THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2020 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2020 2 IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. ANABOLIC AGENTS Anabolic agents are prohibited. 1. ANABOLIC ANDROGENIC STEROIDS (AAS) when administered exogenously, including but not limited to: 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one); 1-Epiandrosterone (3β-hydroxy-5α-androst-1-ene-17-one); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Androstenediol (androst-4-ene-3β,17β-diol); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3- one); 5-Androstenedione (androst-5-ene-3,17-dione); 7α-hydroxy-DHEA; 7β-hydroxy-DHEA; 7-Keto-DHEA; 19-Norandrostenediol (estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α- androstan-3-one); Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Bolasterone; Boldenone; Boldione (androsta-1,4-diene-3,17-dione); S0 S1 Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-androst- 2-en-17β-ol and 17α-methyl-5α-androst-3-en-17β-ol); Drostanolone; Epiandrosterone (3β-hydroxy-5α-androstan-17-one); Epi-dihydrotestosterone (17β-hydroxy-5β-androstan-3- one); Epitestosterone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α- androstan-17β-ol); Gestrinone; Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- 3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- androstan-3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- androst-1-en-3-one); Methylclostebol; Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17α- methylestra-4,9,11-trien-3-one); Mibolerone; Nandrolone (19-nortestosterone); Norboletone; 3 Norclostebol (4-chloro-17β-ol-estr-4-en-3-one); Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H- pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Testosterone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α- pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). 2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, selective androgen receptor modulators [SARMs, e.g. andarine, LGD-4033 (ligandrol), enobosarm (ostarine) and RAD140], tibolone, zeranol and zilpaterol. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoietins (EPO) and agents affecting erythropoiesis, including, but not limited to: 1.1 Erythropoietin-Receptor Agonists, e.g. Darbepoetins (dEPO); Erythropoietins (EPO); EPO based constructs [e.g. EPO-Fc, methoxy polyeth- ylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). 1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. Cobalt; Daprodustat (GSK1278863); Molidustat (BAY 85-3934); Roxadustat (FG-4592); Vadadustat (AKB-6548); Xenon. 1.3 GATA inhibitors, e.g. K-11706. 1.4 TGF-beta (TGF-β) signalling inhibitors, e.g. Luspatercept; Sotatercept. 1.5 Innate repair receptor agonists, e.g. Asialo EPO; Carbamylated EPO (CEPO). S2 4 2. Peptide Hormones and their Releasing Factors, 2.1 Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors in males, e.g. Buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin; 2.2 Corticotrophins and their releasing factors, e.g. Corticorelin; 2.3 Growth Hormone (GH), its fragments and releasing factors, including, but not limited to: Growth Hormone fragments, e.g. AOD-9604 and hGH 176-191; Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. Lenomorelin (ghrelin) and its mimetics, e.g. Anamorelin, ipamorelin, macimorelin and tabimorelin; GH-Releasing Peptides (GHRPs), e.g. Alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin). 3. Growth Factors and Growth Factor Modulators, including, but not limited to: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Thymosin-β4 and its derivatives e.g. TB-500; Vascular-Endothelial Growth Factor (VEGF); and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/ degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. BETA-2 AGONISTS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: Fenoterol; Formoterol; Higenamine; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Salmeterol; Terbutaline; Tretoquinol (trimetoquinol); Tulobuterol; Vilanterol. Except: • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. S3 5 HORMONE AND METABOLIC MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 2-Androstenol (5α-androst-2-en-17-ol); 2-Androstenone (5α-androst-2-en-17-one); 3-Androstenol (5α-androst-3-en-17-ol); 3-Androstenone (5α-androst-3-en-17-one); 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Bazedoxifene; Ospemifene; Raloxifene; Tamoxifen; Toremifene. 3. Other anti-estrogenic substances including, but not limited to: Clomifene; Cyclofenil; Fulvestrant. 4. Agents preventing activin receptor IIB activation including, but not limited, to: Activin A-neutralizing antibodies; Activin receptor IIB competitors such as: Decoy activin receptors (e.g. ACE-031); Anti-activin receptor IIB antibodies (e.g. Bimagrumab); Myostatin inhibitors such as: Agents reducing or ablating myostatin expression; Myostatin-binding proteins (e.g. Follistatin, myostatin propeptide); Myostatin-neutralizing antibodies (e.g. Domagrozumab, S4 landogrozumab, stamulumab). 5. Metabolic modulators: 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl) phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516); 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. Bendroflu- methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. Tolvaptan. Except: • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. Dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. S5 6 PROHIBITED METHODS MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. Haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Sample substitution and/or adulteration, e.g. Addition of proteases to Sample. 2. Intravenous infusions and/or injections of more than a total of 100 mL per 12 hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M1 M2 GENE AND CELL DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies. 3. The use of normal or genetically modified cells. M3 7 IN ADDITION TO THE CLASSES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CLASSES ARE PROHIBITED IN-COMPETITION: SUBSTANCES & METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES STIMULANTS All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include: a: Non-Specified Stimulants: Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-methylamfetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane. A stimulant not expressly listed in this section is a Specified Substance. S6 b: Specified Stimulants: Including, but not limited to: 3-Methylhexan-2-amine (1,2-dimethylpentylamine); 4-Methylhexan-2-amine (methylhexaneamine); 4-Methylpentan-2-amine (1,3-dimethylbutylamine); 5-Methylhexan-2-amine (1,4-dimethylpentylamine); Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone, methedrone, and α - pyrrolidinovalerophenone; Dimetamfetamine (dimethylamphetamine); Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***; Methylphenidate; Nikethamide; Norfenefrine; Octodrine (1,5-dimethylhexylamine); Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; 8 Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). Except: • Clonidine; • Imidazole derivatives for dermatological, nasal or ophthalmic use and those stimulants included in the 2020 Monitoring Program*. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2020 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter. NARCOTICS The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited: Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Nicomorphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine. CANNABINOIDS All natural and synthetic cannabinoids are prohibited, e.g. • In cannabis (hashish, marijuana) and cannabis products • Natural and synthetic tetrahydrocannabinols (THCs) • Synthetic cannabinoids that mimic the effects of THC Except: • Cannabidiol. GLUCOCORTICOIDS All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. Including but not limited to: Betamethasone; Budesonide; Cortisone; Deflazacort; Dexamethasone; Fluticasone; Hydrocortisone; Methylprednisolone; Prednisolone; Prednisone; Triamcinolone. S7 S8 S9 9 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS BETA-BLOCKERS Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated. • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea. *Also prohibited Out-of-Competition Including, but not limited to: Acebutolol; Labetalol; Alprenolol; Metipranolol; Atenolol; Metoprolol; Betaxolol; Nadolol; Bisoprolol; Oxprenolol; Bunolol; Pindolol; Carteolol; Propranolol; Carvedilol; Sotalol; Celiprolol; Timolol. Esmolol; P1 www.wada-ama.org

1 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES Redesign of the List • The 2021 Prohibited List is redesigned to improve navigation and usability. Specified Methods • M2.2 is now a Specified Method in accordance with Article 4.2.2 of the 2021 World Anti-Doping Code (the Code). Substances of Abuse • Article 4.2.3 of the Code defines Substances of Abuse as those “Prohibited Substances which are specifically identified as Substances of Abuse on the Prohibited List because they are frequently abused in society outside of the context of sport.” • Cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/“ecstasy”) and tetrahydrocannabinol (THC) are designated as Substances of Abuse. • Other substances are currently under review and may be designated as Substances of Abuse in the future. 2021 Prohibited List 2 S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics • Transforming growth factor-beta (TGF-β) signalling inhibitors are now included with their full rather than abbreviated name. • IOX2 is added as an example of a hypoxia-inducible factor (HIF) activating agent. S3. Beta-2 Agonists • Inhaled vilanterol is now permitted up to the manufacturer’s maximum recommended dose. The dose is expressed as the metered dose of 25 micrograms which is equivalent to a delivered dose of 22 micrograms. • It is clarified that arformoterol and levosalbutamol are prohibited by adding them as examples. S4. Hormone and Metabolic Modulators • Sub-classes 4.2 and 4.3 were amalgamated to become anti-estrogenic substances (including selective estrogen receptor modulators (SERMs)). This clarification in terminology reflects that, for anti-doping purposes, all these substances act by a common mechanism of binding to estrogen receptors and blocking estrogen action. This clarification did not add or remove any substances from this category. S5. Diuretics and Masking Agents • The wording regarding the exception to allow the ophthalmic use of carbonic anhydrase inhibitors is clarified as “topical ophthalmic administration”. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES M2. Chemical and Physical Manipulation • As explained above, M2.2 is changed from a non-Specified to a Specified Method. PROHIBITED METHODS 3 S6. Stimulants • Examples of imidazole derivatives for topical use are added to the exceptions. These are brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline and xylometazoline. S9. Glucocorticoids • Additional examples of glucocorticoids are added to the List. The names of some existing examples are clarified to better reflect the active drug compound. • As proposed in the draft 2021 Prohibited List circulated for consultation to stakeholders in May 2020, WADA’s Executive Committee approved, at its 14-15 September 2020 meeting, prohibiting all injectable routes of administration of glucocorticoids during the In-Competition period. Examples of injectable routes of administration include: intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g. intrakeloid), intradermal, and subcutaneous. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of all injectable glucocorticoid routes and the implementation of the new rules on 1 January 2022. This one-year period will allow, for example, Athletes and medical personnel to get a better understanding of the practical implementation of the washout periods, Laboratories to update their procedures to incorporate the revised and substance-specific new reporting values, and sports authorities to develop educational tools for Athletes, medical and support personnel, addressing the safe use of glucocorticoids for clinical purposes in anti-doping. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES P1. Beta-blockers • Nebivolol was added as an example. 4 Beta-2 Agonists: In and Out-of-Competition: • Any combination of beta-2 agonists was removed as the required prevalence data were obtained. • Findings for salmeterol and vilanterol below the Minimum Reporting Level are included in the Monitoring Program to better monitor their therapeutic use vs risk of abuse. * For further information on previous modifications and clarifications, please consult the Prohibited List Q & A at www.wada-ama.org/en/questions-answers/prohibited-list-qa. MONITORING PROGRAM

1 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES Redesign of the List • The 2021 Prohibited List is redesigned to improve navigation and usability. Specified Methods • M2.2 is now a Specified Method in accordance with Article 4.2.2 of the 2021 World Anti-Doping Code (the Code). Substances of Abuse • Article 4.2.3 of the Code defines Substances of Abuse as those “Prohibited Substances which are specifically identified as Substances of Abuse on the Prohibited List because they are frequently abused in society outside of the context of sport.” • Cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/“ecstasy”) and tetrahydrocannabinol (THC) are designated as Substances of Abuse. • Other substances are currently under review and may be designated as Substances of Abuse in the future. 2021 Prohibited List 2 S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics • Transforming growth factor-beta (TGF-β) signalling inhibitors are now included with their full rather than abbreviated name. • IOX2 is added as an example of a hypoxia-inducible factor (HIF) activating agent. S3. Beta-2 Agonists • Inhaled vilanterol is now permitted up to the manufacturer’s maximum recommended dose. The dose is expressed as the metered dose of 25 micrograms which is equivalent to a delivered dose of 22 micrograms. • It is clarified that arformoterol and levosalbutamol are prohibited by adding them as examples. S4. Hormone and Metabolic Modulators • Sub-classes 4.2 and 4.3 were amalgamated to become anti-estrogenic substances (including selective estrogen receptor modulators (SERMs)). This clarification in terminology reflects that, for anti-doping purposes, all these substances act by a common mechanism of binding to estrogen receptors and blocking estrogen action. This clarification did not add or remove any substances from this category. S5. Diuretics and Masking Agents • The wording regarding the exception to allow the ophthalmic use of carbonic anhydrase inhibitors is clarified as “topical ophthalmic administration”. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES M2. Chemical and Physical Manipulation • As explained above, M2.2 is changed from a non-Specified to a Specified Method. PROHIBITED METHODS 3 S6. Stimulants • Examples of imidazole derivatives for topical use are added to the exceptions. These are brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline and xylometazoline. S9. Glucocorticoids • Additional examples of glucocorticoids are added to the List. The names of some existing examples are clarified to better reflect the active drug compound. • As proposed in the draft 2021 Prohibited List circulated for consultation to stakeholders in May 2020, WADA’s Executive Committee approved, at its 14-15 September 2020 meeting, prohibiting all injectable routes of administration of glucocorticoids during the In-Competition period. Examples of injectable routes of administration include: intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g. intrakeloid), intradermal, and subcutaneous. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of all injectable glucocorticoid routes and the implementation of the new rules on 1 January 2022. This one-year period will allow, for example, Athletes and medical personnel to get a better understanding of the practical implementation of the washout periods, Laboratories to update their procedures to incorporate the revised and substance-specific new reporting values, and sports authorities to develop educational tools for Athletes, medical and support personnel, addressing the safe use of glucocorticoids for clinical purposes in anti-doping. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES P1. Beta-blockers • Nebivolol was added as an example. 4 Beta-2 Agonists: In and Out-of-Competition: • Any combination of beta-2 agonists was removed as the required prevalence data were obtained. • Findings for salmeterol and vilanterol below the Minimum Reporting Level are included in the Monitoring Program to better monitor their therapeutic use vs risk of abuse. * For further information on previous modifications and clarifications, please consult the Prohibited List Q & A at www.wada-ama.org/en/questions-answers/prohibited-list-qa. MONITORING PROGRAM

1 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES 2022 Prohibited List S1. Anabolic Agents • Tibolone is transferred from S1.2 to S1.1 because it has clinical effects as a synthetic oral androgen mediated by effects on the androgen receptor, largely due to its conversion to the delta-4 tibolone metabolite, which is a potent androgen. • Osilodrostat, a CYP11B1 inhibitor, is added to S1.2 due to its off-target increase in circulating testosterone. S3. Beta-2 Agonists • The daily dosing time intervals for salbutamol are modified to 600 micrograms over 8 hours starting from the time any dose is taken (previously 800 micrograms over 12 hours). This is to reduce the risk of any potential Adverse Analytical Finding arising after high doses are taken at once. • The total permitted daily dose remains at 1600 micrograms over 24 hours. A Therapeutic Use Exemption (TUE) should be sought for doses in excess of these limits. • For example, an athlete could take 600 micrograms in the first 8 hours, 600 micrograms in the following 8 hours, and 400 micrograms in the remaining 8 hours of the day, without the need for a TUE. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. Non-approved Substances • BPC-157 is now prohibited under S0 following a recent re-evaluation and added as an example. S2. Peptide hormones, growth factors, related substances and mimetics • Lonapegsomatropin, somapacitan and somatrogon are added as examples of growth hormone analogues, which led to the reorganization and splitting of S2.2.3. 2 S6. Stimulants • S.6 Exceptions: Imidazole derivatives was changed to imidazoline derivatives to distinguish between generic imidazole derivatives and sympathomimetic imidazolines. • Cathine footnote: It was clarified that the urinary threshold of 5 µg/mL cathine refers to both isomers of norpseudoephedrine, i.e. the d-and the l-isomer (also referred to as 1S,2S- and 1R,2R- norpseudoephedrine, respectively). • Ethylphenidate, methylnaphthidate ((±)-methyl-2-(naphthalen-2-yl)-2- (piperidin-2-yl)acetate) and 4-fluoromethylphenidate are added to S6.b as examples of methylphenidate analogues. These substances have been prevalent in a number of countries over the past decade as they are often presented as alternatives to methylphenidate. • Hydrafinil (fluorenol) is added to S6.b as an example of modafinil and adrafinil analogue. S9. Glucocorticoids • Flucortolone is updated to its International Non-proprietary Name (INN), fluocortolone. • All injectable routes of administration are now prohibited for glucocorticoids during the In- Competition period. As proposed in the draft 2021 Prohibited List circulated for consultation to stakeholders in May 2020, WADA’s Executive Committee approved at its 14-15 September 2020 meeting prohibition of all injectable routes of administration of glucocorticoids during the In-Competition period. Examples of injectable routes of administration include: intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g. intrakeloid), intradermal, and subcutaneous. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of all injectable glucocorticoid routes and the implementation of the new rules on 1 January 2022. This allows, for example, Athletes and medical personnel to get a better understanding of the practical implementation of the washout periods, Laboratories to update their procedures to incorporate the revised and substance-specific new minimum reporting levels (MRL), and sports authorities to develop educational tools for Athletes, medical and support personnel to address the safe use of glucocorticoids for clinical purposes and prevent doping. • For clarification, oral administration of glucocorticoids also includes oromucosal, buccal, gingival and sublingual routes. Dental-intracanal application is not prohibited. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES 3 • Oral, intramuscular, rectal and intravenous routes were prohibited because there is clear evidence of systemic effects which could potentially enhance performance and be harmful to health. There are now also sufficient data available to show that the same systemic concentrations as existing prohibited routes can be achieved after administration by local injection (including periarticular, intra-articular, peritendinous and intratendinous) at licensed therapeutic doses. • The systemic plasma and hence urinary concentrations of glucocorticoids that are reached after administration by local injection using normal licensed therapeutic doses were demonstrated to reach levels consistent with doses that were shown to have the potential to improve performance in clinical studies. These levels are similar to, and even higher than, those obtained after other existing prohibited routes of administration of the same drug. The systemic effect of glucocorticoids following local injectable routes of administration may therefore present a significant potential to both improve performance and cause harm to health. Addition of local injections as prohibited routes Explanation of the approach taken • Glucocorticoids include naturally occurring hormones and synthetic analogues and possess a wide range of potencies and pharmacokinetic properties. The body naturally produces a daily output of the endogenous glucocorticoid (cortisol). However, administering glucocorticoid drugs can result in a total glucocorticoid exposure to the body that is much greater than the highest levels of normal physiological cortisol production, which could potentially be performance enhancing. • The administration of glucocorticoid medications by inhaled, or topical routes (including dental-intracanal, dermal, intranasal, ophthalmological and perianal), in accordance with the manufacturer’s approved dosing regimen, are unlikely to reach systemic concentrations which may be performance enhancing. • However, for other routes of administration (for example, oral), studies involving commonly used glucocorticoids at the normal therapeutic dose range indicated a performance-enhancing effect. These doses can be expressed in terms of cortisol-equivalents and thereby the dose which may be potentially performance enhancing for any glucocorticoid and route of administration can be determined using this approach. • This systematic approach was applied to determine the glucocorticoid routes of administration that are either prohibited or not prohibited in sport. Consequently, revised and substance-specific laboratory MRL based on excretion studies are introduced to better reflect the proposed approach. To note, the revised MRL are increased or remain unchanged for all glucocorticoids except triamcinolone acetonide, which was revised to a lower MRL. Overall, these changes should reduce the number of Adverse Analytical Findings reported by laboratories. 4 Washout periods following administration of glucocorticoids • Any injection of glucocorticoids is prohibited In-Competition. Given the widespread availability and the common use of glucocorticoids in sports medicine, Athletes and their Support Personnel are advised of the following: 1. Use of a glucocorticoid by injection during the In-Competition period requires a Therapeutic Use Exemption; otherwise, an alternative permitted medication in consultation with a physician shall be used. 2. After administration of glucocorticoids, urinary MRL which would result in an Adverse Analytical Finding can be reached for different periods of time after administration (ranging from days to weeks), depending on the glucocorticoid administered and the dose. To reduce the risk of an Adverse Analytical Finding, Athletes should follow the minimum washout periods*, expressed from the time of administration to the start of the In-Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). These washout periods are based on the use of these medications according to the maximum manufacturer’s licensed doses: Route Glucocorticoid Washout period* Oral** All glucocorticoids; 3 days Except: triamcinolone ace- tonide 30 days Intramuscular Betamethasone; dexametha- sone; methylprednisolone 5 days Prednisolone; prednisone 10 days Triamcinolone acetonide 60 days Local injections (including periarticular, intra-articular, peritendinous and intraten- dinous) All glucocorticoids; 3 days Except: triamcinolone ace- tonide; prednisolone; predni- sone 10 days * Washout period refers to the time from the last administered dose to the time of the start of the In- Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). This is to allow elimination of the glucocorticoid to below the reporting level. ** Oral routes also include e.g. oromucosal, buccal, gingival and sublingual. 3. If the glucocorticoid needs to be administered via a prohibited route within these washout time periods, a Therapeutic Use Exemption (TUE) may be required. Physicians administering local injections of glucocorticoids should be aware that periarticular or intra-articular injection may sometimes inadvertently result in intramuscular administration. If intramuscular administration is suspected, the washout periods for the intramuscular route should be observed, or a TUE application sought. 5 P1. Beta-blockers • Underwater Sports (CMAS) subdisciplines were regrouped. This change does not affect the current subdisciplines where beta-blockers are prohibited. • For additional information including the revised MRL, please consult the recently published article with details of the process that lead to these changes: https://bjsm.bmj.com/content/ early/2021/04/19/bjsports-2020-103512.full?ijkey=APWRPYVYjy69LOH&keytype=ref 4. Please note that as per Article 4.1e of the International Standard for TUEs, an Athlete may apply retroactively for a TUE if the Athlete Used Out-of-Competition, for therapeutic reasons, a Prohibited Substance that is only prohibited In-Competition. Athletes are strongly advised to have a medical file prepared and ready to demonstrate their satisfaction of the TUE conditions set out at Article 4.2, in case an application for a retroactive TUE is necessary following Sample collection. https://bjsm.bmj.com/content/early/2021/04/19/bjsports-2020-103512.full?ijkey=APWRPYVYjy69LOH&keytype=ref https://bjsm.bmj.com/content/early/2021/04/19/bjsports-2020-103512.full?ijkey=APWRPYVYjy69LOH&keytype=ref 6 • The monitoring of bemitil, and glucocorticoids is discontinued as the required prevalence data were obtained. * For further information on previous modifications and clarifications, please consult the Prohibited List Q & A at www.wada-ama.org/en/questions-answers/prohibited-list-qa. MONITORING PROGRAM https://www.wada-ama.org/en/questions-answers/prohibited-list-qa

1 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES 2022 Prohibited List S1. Anabolic Agents • Tibolone is transferred from S1.2 to S1.1 because it has clinical effects as a synthetic oral androgen mediated by effects on the androgen receptor, largely due to its conversion to the delta-4 tibolone metabolite, which is a potent androgen. • Osilodrostat, a CYP11B1 inhibitor, is added to S1.2 due to its off-target increase in circulating testosterone. S3. Beta-2 Agonists • The daily dosing time intervals for salbutamol are modified to 600 micrograms over 8 hours starting from the time any dose is taken (previously 800 micrograms over 12 hours). This is to reduce the risk of any potential Adverse Analytical Finding arising after high doses are taken at once. • The total permitted daily dose remains at 1600 micrograms over 24 hours. A Therapeutic Use Exemption (TUE) should be sought for doses in excess of these limits. • For example, an athlete could take 600 micrograms in the first 8 hours, 600 micrograms in the following 8 hours, and 400 micrograms in the remaining 8 hours of the day, without the need for a TUE. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. Non-approved Substances • BPC-157 is now prohibited under S0 following a recent re-evaluation and added as an example. S2. Peptide hormones, growth factors, related substances and mimetics • Lonapegsomatropin, somapacitan and somatrogon are added as examples of growth hormone analogues, which led to the reorganization and splitting of S2.2.3. 2 S6. Stimulants • S.6 Exceptions: Imidazole derivatives was changed to imidazoline derivatives to distinguish between generic imidazole derivatives and sympathomimetic imidazolines. • Cathine footnote: It was clarified that the urinary threshold of 5 µg/mL cathine refers to both isomers of norpseudoephedrine, i.e. the d-and the l-isomer (also referred to as 1S,2S- and 1R,2R- norpseudoephedrine, respectively). • Ethylphenidate, methylnaphthidate ((±)-methyl-2-(naphthalen-2-yl)-2- (piperidin-2-yl)acetate) and 4-fluoromethylphenidate are added to S6.b as examples of methylphenidate analogues. These substances have been prevalent in a number of countries over the past decade as they are often presented as alternatives to methylphenidate. • Hydrafinil (fluorenol) is added to S6.b as an example of modafinil and adrafinil analogue. S9. Glucocorticoids • Flucortolone is updated to its International Non-proprietary Name (INN), fluocortolone. • All injectable routes of administration are now prohibited for glucocorticoids during the In- Competition period. As proposed in the draft 2021 Prohibited List circulated for consultation to stakeholders in May 2020, WADA’s Executive Committee approved at its 14-15 September 2020 meeting prohibition of all injectable routes of administration of glucocorticoids during the In-Competition period. Examples of injectable routes of administration include: intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g. intrakeloid), intradermal, and subcutaneous. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of all injectable glucocorticoid routes and the implementation of the new rules on 1 January 2022. This allows, for example, Athletes and medical personnel to get a better understanding of the practical implementation of the washout periods, Laboratories to update their procedures to incorporate the revised and substance-specific new minimum reporting levels (MRL), and sports authorities to develop educational tools for Athletes, medical and support personnel to address the safe use of glucocorticoids for clinical purposes and prevent doping. • For clarification, oral administration of glucocorticoids also includes oromucosal, buccal, gingival and sublingual routes. Dental-intracanal application is not prohibited. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES 3 • Oral, intramuscular, rectal and intravenous routes were prohibited because there is clear evidence of systemic effects which could potentially enhance performance and be harmful to health. There are now also sufficient data available to show that the same systemic concentrations as existing prohibited routes can be achieved after administration by local injection (including periarticular, intra-articular, peritendinous and intratendinous) at licensed therapeutic doses. • The systemic plasma and hence urinary concentrations of glucocorticoids that are reached after administration by local injection using normal licensed therapeutic doses were demonstrated to reach levels consistent with doses that were shown to have the potential to improve performance in clinical studies. These levels are similar to, and even higher than, those obtained after other existing prohibited routes of administration of the same drug. The systemic effect of glucocorticoids following local injectable routes of administration may therefore present a significant potential to both improve performance and cause harm to health. Addition of local injections as prohibited routes Explanation of the approach taken • Glucocorticoids include naturally occurring hormones and synthetic analogues and possess a wide range of potencies and pharmacokinetic properties. The body naturally produces a daily output of the endogenous glucocorticoid (cortisol). However, administering glucocorticoid drugs can result in a total glucocorticoid exposure to the body that is much greater than the highest levels of normal physiological cortisol production, which could potentially be performance enhancing. • The administration of glucocorticoid medications by inhaled, or topical routes (including dental-intracanal, dermal, intranasal, ophthalmological and perianal), in accordance with the manufacturer’s approved dosing regimen, are unlikely to reach systemic concentrations which may be performance enhancing. • However, for other routes of administration (for example, oral), studies involving commonly used glucocorticoids at the normal therapeutic dose range indicated a performance-enhancing effect. These doses can be expressed in terms of cortisol-equivalents and thereby the dose which may be potentially performance enhancing for any glucocorticoid and route of administration can be determined using this approach. • This systematic approach was applied to determine the glucocorticoid routes of administration that are either prohibited or not prohibited in sport. Consequently, revised and substance-specific laboratory MRL based on excretion studies are introduced to better reflect the proposed approach. To note, the revised MRL are increased or remain unchanged for all glucocorticoids except triamcinolone acetonide, which was revised to a lower MRL. Overall, these changes should reduce the number of Adverse Analytical Findings reported by laboratories. 4 Washout periods following administration of glucocorticoids • Any injection of glucocorticoids is prohibited In-Competition. Given the widespread availability and the common use of glucocorticoids in sports medicine, Athletes and their Support Personnel are advised of the following: 1. Use of a glucocorticoid by injection during the In-Competition period requires a Therapeutic Use Exemption; otherwise, an alternative permitted medication in consultation with a physician shall be used. 2. After administration of glucocorticoids, urinary MRL which would result in an Adverse Analytical Finding can be reached for different periods of time after administration (ranging from days to weeks), depending on the glucocorticoid administered and the dose. To reduce the risk of an Adverse Analytical Finding, Athletes should follow the minimum washout periods*, expressed from the time of administration to the start of the In-Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). These washout periods are based on the use of these medications according to the maximum manufacturer’s licensed doses: Route Glucocorticoid Washout period* Oral** All glucocorticoids; 3 days Except: triamcinolone ace- tonide 30 days Intramuscular Betamethasone; dexametha- sone; methylprednisolone 5 days Prednisolone; prednisone 10 days Triamcinolone acetonide 60 days Local injections (including periarticular, intra-articular, peritendinous and intraten- dinous) All glucocorticoids; 3 days Except: triamcinolone ace- tonide; prednisolone; predni- sone 10 days * Washout period refers to the time from the last administered dose to the time of the start of the In- Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). This is to allow elimination of the glucocorticoid to below the reporting level. ** Oral routes also include e.g. oromucosal, buccal, gingival and sublingual. 3. If the glucocorticoid needs to be administered via a prohibited route within these washout time periods, a Therapeutic Use Exemption (TUE) may be required. Physicians administering local injections of glucocorticoids should be aware that periarticular or intra-articular injection may sometimes inadvertently result in intramuscular administration. If intramuscular administration is suspected, the washout periods for the intramuscular route should be observed, or a TUE application sought. 5 P1. Beta-blockers • Underwater Sports (CMAS) subdisciplines were regrouped. This change does not affect the current subdisciplines where beta-blockers are prohibited. • For additional information including the revised MRL, please consult the recently published article with details of the process that lead to these changes: https://bjsm.bmj.com/content/ early/2021/04/19/bjsports-2020-103512.full?ijkey=APWRPYVYjy69LOH&keytype=ref 4. Please note that as per Article 4.1e of the International Standard for TUEs, an Athlete may apply retroactively for a TUE if the Athlete Used Out-of-Competition, for therapeutic reasons, a Prohibited Substance that is only prohibited In-Competition. Athletes are strongly advised to have a medical file prepared and ready to demonstrate their satisfaction of the TUE conditions set out at Article 4.2, in case an application for a retroactive TUE is necessary following Sample collection. https://bjsm.bmj.com/content/early/2021/04/19/bjsports-2020-103512.full?ijkey=APWRPYVYjy69LOH&keytype=ref https://bjsm.bmj.com/content/early/2021/04/19/bjsports-2020-103512.full?ijkey=APWRPYVYjy69LOH&keytype=ref 6 • The monitoring of bemitil, and glucocorticoids is discontinued as the required prevalence data were obtained. * For further information on previous modifications and clarifications, please consult the Prohibited List Q & A at www.wada-ama.org/en/questions-answers/prohibited-list-qa. MONITORING PROGRAM https://www.wada-ama.org/en/questions-answers/prohibited-list-qa

1 Summary of Major Modifications and Explanatory Notes 2023 Prohibited List SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. Anabolic Agents • Androst-4-ene-3,11,17-trione (11-ketoandrostenedione, adrenosterone) is now listed as an example. In the body, it is converted to 11-ketotestosterone and both are androgens already prohibited as metabolites of androstenedione and testosterone, respectively. • The substance 17ɑ-methylepithiostanol (commonly referred to as epistane) is the 17-methylated analog to thiodrol (Shionogi, Japan) and converts in vivo to the prohibited anabolic agent desoxymethyltestosterone. Hence, per definition, 17ɑ-methylepithiostanol is also prohibited under S1. In order to unequivocally document the prohibited status of 17ɑ-methylepithiostanol, the substance was added as an additional example. • Ractopamine, a beta-adrenergic agonist approved in some countries as a growth promoter for animals, was added to the list of examples under S1.2. • S-23 and YK-11 were listed as examples of SARMs in S1.2. S4. Hormone and Metabolic Modulators • S4.3 was updated to include antibodies of precursors of myostatin and as example, apitegromab was added. • The numbering was reformatted for clarity but there was no change in classification. 2 S5. Diuretics and Masking Agents • The introductory language of the section was revised to harmonize with other sections of the List. • Torasemide is added as an example of a diuretic and is already named in a WADA Technical Document (TD MRPL) and a WADA Technical Letter (TL24). • It was clarified that a Therapeutic Use Exemption is not required for topical ophthalmic administration of a carbonic anhydrase inhibitor (e.g. dorzolamide, brinzolamine) or for local administration of felypressin in dental anesthesia in conjunction with a threshold substance. 3 PROHIBITED METHODS M1. Manipulation of Blood and Blood Components • Voxelotor was added as an example, as it alters the ability of hemoglobin to release oxygen in the body, thereby enhancing arterial oxygen saturation. As a side effect, it increases serum erythropoietin, which has been shown to result in higher hemoglobin concentration in healthy individuals. 4 S6. Stimulants • 1,3-dimethylamylamine and 1,3 DMAA were added as alternative common names for 4-methylhexan-2-amine, while 1,4-dimethylamylamine and 1,4-DMAA were included as synonyms of 5-methylhexan-2-amine. • Solriamfetol was included in S6b due to its activity as a dopamine and norepinephrine reuptake inhibitor resulting in increases in brain levels of these neurotransmitters and consequent stimulant behavioral effects in preclinical species and in humans. • Tetryzoline was added as an imidazoline derivative under Exceptions. In addition, it is clarified that otic administration of imidazoline derivatives is not prohibited. S7. Narcotics SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES 1 a) Holgado D, Zandonai T, Zabala M, Hopker J, Perakakis P, Luque-Casado A, Ciria L, Guerra-Hernandez E, Sanabria D. Tramadol effects on physical performance and sustained attention during a 20-min indoor cycling time-trial: A randomised controlled trial. J Sci Med Sport. 2018 Jul;21(7):654-660. b) Mauger L, Thomas T, Smith S, Fennell C. (2022). Is tramadol a performance enhancing drug? A randomised controlled trial. British Association of Sport and Exercise Medicine Conference, 26-27 May 2022, Brighton, UK. https://basem.co.uk/wp-content/uploads/2022/08/Mauger_BASEM-Abstract.pdf https://www.wada-ama.org/en/resources/funded-scientific-research/tramadol-performance-enhancing-drug • Tramadol has been on the WADA Monitoring Program for some years. Monitoring data has indicated significant Use in sports including cycling, rugby and football. Tramadol abuse, with its dose-dependent risks of physical dependence, opiate addiction and overdoses in the general population, is of concern and has led to it being a controlled drug in many countries. Research studies funded by WADA1 have confirmed the potential for tramadol to enhance physical performance in sports. Consequently, as proposed in the draft 2023 Prohibited List circulated for consultation to stakeholders in May 2022, WADA’s Executive Committee approved, at its 23 September 2022 meeting, prohibiting tramadol during the In-Competition period. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of tramadol and the implementation of the new rule on 1 January 2024. A one-year delay in implementation will allow Athletes and medical personnel to better prepare for the change, Laboratories to update their procedures, and sports authorities to develop educational tools. S9. Glucocorticoids • It was clarified that otic administration of glucocorticoids is not prohibited. 5 P1. Beta-Blockers • At the request of the World Mini-Golf Federation (WMF), it was agreed to include mini- golf as a sport where beta-blockers are prohibited. The skills required for mini-golf are similar to others found in sports disciplines where beta-blockers are prohibited. • At the request of the World Under Water Federation (CMAS) beta-blockers will be prohibited Out-of-competition as well as In-competition in all subdisciplines of freediving, spearfishing and target shooting. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS 6 • Dermorphin and its analogs were added to detect patterns of use in sport In- competition. • GnRH analogs in females under 18 years were added to detect patterns of use in sport In- and Out-of-competition. • Hypoxen (polyhydroxyphenylene thiosulfonate sodium) was added to evaluate misuse in sport In- and Out-of-competition. * For further information on previous modifications and clarifications, please consult the Prohibited List Frequently Asked Questions at https://www.wada-ama.org/en/ prohibited-list#faq-anchor. MONITORING PROGRAM https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor 7 ADDENDUM Background • Following receipt of requests from a small number of stakeholders to remove (three national anti-doping organizations and one sports federation) or review (two anti-doping organizations) the prohibited In-competition status of cannabis from the Prohibited List, the WADA Executive Committee endorsed, during its meeting of September 2021, a recommendation of the WADA List Expert Advisory Group (LiEAG) to initiate a scientific review of the status of cannabis in 2022. • At present, the main psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), is prohibited In-competition and is reported as an Adverse Analytical Finding (AAF) by WADA-accredited laboratories when the urinary concentration- of carboxy- THC exceeds a threshold of 150 ng/mL with a Decision Limit of 180 ng/mL. This threshold was significantly increased in 2013 from 15 ng/mL in order to minimize the number of AAFs In-competition due to potential Use of THC Out-of-competition. This means that with the current threshold, Athletes most at risk of testing positive are those who have consumed significant quantities of THC close to In-competition Doping Control or are chronic users. • The 2021 World Anti-Doping Code (Code) incorporated the new Article 4.2.3 on Substances of Abuse for purposes of sanctioning under Code Article 10. Substances of Abuse are specifically identified on the Prohibited List because they are frequently abused in society outside of the context of sport. In this regard, the LiEAG identified THC as a Substance of Abuse for the 2021 Prohibited List, meaning that if the Athlete can establish that the THC use occurred Out-of-Competition and was unrelated to sport performance, the standard period of Ineligibility is three months, which may be reduced to one month if the Athlete satisfactorily completes an approved Substance of Abuse treatment program. While it is too early to evaluate the full impact of this new rule on sanctions for THC, preliminary data from 2021 indicates an increase in one- and three- month sanctions, suggesting that this provision is being applied. • Under the World Anti-Doping Program, the approach to cannabis on the Prohibited List has therefore evolved chronologically as follows: 2013: The urinary threshold increased from 15 ng/mL to 150 ng/mL with a Decision Limit of 180 ng/ ml. This significantly affected the number of AAFs, from an average of between 400-500 per annum in the years 2009-2012 to fewer than 100 in 2021. 2018: Cannabidiol (CBD) was removed from the Prohibited List, allowing Athletes who wish to use it to have access to the non-psychoactive component of cannabis. 2021: The inclusion of the Substance of Abuse provision in the Code significantly reduced the length of Ineligibility sanctions from a potential two (or even four) years previously to three (or even one) month(s) today for Athletes that can establish that the THC use occurred Out-of-Competition and was unrelated to sport performance. Under Article 9 of the Code, the Athlete will still lose their medal, prize and result. S8. Cannabinoids 8 The Review Process: • Since September 2021, the LiEAG, which is composed of external, international experts in pharmacology, forensic toxicology, drugs of abuse, analytical science, pharmacy, sports medicine, chemistry, endocrinology, internal medicine, regulatory affairs, peptides and growth factors and hematology embarked on a full de novo review of the status of delta9-tetrahydrocannabinol (THC) in sport. This extensive review focused on the three criteria set forth by Article 4.3 of the 2021 Code, namely: a. Medical or other scientific evidence, pharmacological effect or experience that the substance or method, alone or in combination with other substances or methods, has the potential to enhance or enhances sport performance; b. Medical or other scientific evidence, pharmacological effects or experience that the Use of the substance or method represents an actual or potential health risk to the Athlete; c. WADA’s determination that the Use of the substance or method contravenes the spirit of sport described in the introduction to the Code. • Under Code Article 4.3, a substance or method must meet at least two of these three criteria to be considered for inclusion in the Prohibited List. • Two subgroups of members of the LiEAG were formed, one to evaluate the effects of THC on performance enhancement (LiEAG-PE) and the other to assess the health risks (LiEAG-H). All existing scientific and medical publications related to these two topics were reviewed, as well as testimonials from Athletes who were/are cannabis users, available publicly, including in published surveys. • This scientific literature review was subsequently discussed with four world-renowned independent, external international experts (Ad-Hoc THC Expert Group) specialized in the pharmacology, toxicology, psychiatry and behavioral properties of THC and cannabinoids, to ensure that all relevant publications had been included and that all relevant scientific and medical aspects had been appropriately evaluated. The experts confirmed that the information review had been extensive and that all relevant data and aspects of the impact of THC on health and performance enhancement had been properly examined. • With respect to the Spirit of Sport criterion, the LiEAG Chair consulted with the WADA Ethics Expert Advisory Group (Ethics EAG). The Ethics EAG considered cannabis Use, at this time, to be against the Spirit of Sport across a cluster of areas listed in the Code, in particular: • Health • Excellence in Performance • Character and Education • Respect for rules and laws • Respect for self and other participants They also noted that: • Further research should be undertaken or supported in relation to Athletes’ perceptions of cannabis Use but also in relation to its potential (including placebo-induced) enhancing effects. These are areas of uncertainty owing to a lack of robust evidence. 9 Conclusions: After a thorough assessment and discussion under WADA Code Article 4.3, the LiEAG concluded that: a. There is compelling medical evidence that Use of THC is a risk for health, mainly neurological, that has a significant impact on the health of young individuals, a cohort which is overrepresented in Athletes. b. The current body of objective evidence does not support THC enhancement of physiological performance, while the potential for performance enhancement through neuropsychological effects still cannot be excluded. c. In consideration of the values encompassed by the Spirit of Sport as outlined by the Ethics EAG, and noting in particular that respect for self and other participants includes the safety of fellow-competitors, the Use of THC In-competition violates the Spirit of Sport. Based on these three criteria defined by the Code, on the scientific evidence available, THC meets the criteria to be included on the List. • Levels to trigger an Anti-Doping Rule Violation In-competition are such that they would be problematic on medical grounds for a competing Athlete, or indicative of a chronic habitual user. The present rule is not, as sometimes perceived or represented, an excessive incursion into private lifestyles. Nevertheless, and mindful of shifting public attitudes and laws in certain countries, the weight of evidence and argument, along with broad international restrictive regulatory laws and policies, supports the continuance of cannabis on the Prohibited List at this time. • The LiEAG Chair also consulted with the members of the WADA Athlete Committee to seek their opinions on the Use of cannabis in sport. The meeting reflected the range of opinions and views of the Athlete community. • In total, there were 10 consultative meetings held prior to the latest meeting of the LiEAG on 25-26 April 2022: • three by the LiEAG-PE • two by the LiEAG-H • one between the LiEAG Chair and the Athlete Committee Chair • one between the LiEAG Chair and the Athlete Committee • one between the LiEAG Chair and the Ethics EAG • one between the Ad-Hoc THC Expert Group and the LiEAG-PE • one between the Ad-Hoc THC Expert Group and the LiEAG-H 10 Future considerations: • These conclusions are based on the currently available scientific literature. From the extensive review conducted, it was evident that there is a lack of robust studies evaluating the performance enhancing effects of THC at both the physical and mental level. While anecdotal, self-reported evidence is available, further clinical studies are required to rigorously determine the neuropsychological impact of THC on performance. However, it is also acknowledged that such studies may be difficult to design. For example, it would require enrolling volunteers actively consuming THC, which in most countries is illegal; it would not be a truly blinded placebo study because the subject would feel the effect of THC leading to possible positive bias (to show it has performance enhancing effects and thus should be prohibited) or negative bias (to support exclusion from the List); it would be difficult to re-create the stress of a competition; and it is very unlikely that high level Athletes could be included as volunteers. Therefore, only those using cannabis and in regions where THC use is legal could be recruited, and in an Out-of-competition setting, with a risk of positive or negative bias. • As with all substances that are prohibited In-competition only, Athletes in regions where cannabis use is legal are advised to refrain from consuming cannabis for a number of days before the start of competition.

1 Summary of Major Modifications and Explanatory Notes 2023 Prohibited List SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. Anabolic Agents • Androst-4-ene-3,11,17-trione (11-ketoandrostenedione, adrenosterone) is now listed as an example. In the body, it is converted to 11-ketotestosterone and both are androgens already prohibited as metabolites of androstenedione and testosterone, respectively. • The substance 17ɑ-methylepithiostanol (commonly referred to as epistane) is the 17-methylated analog to thiodrol (Shionogi, Japan) and converts in vivo to the prohibited anabolic agent desoxymethyltestosterone. Hence, per definition, 17ɑ-methylepithiostanol is also prohibited under S1. In order to unequivocally document the prohibited status of 17ɑ-methylepithiostanol, the substance was added as an additional example. • Ractopamine, a beta-adrenergic agonist approved in some countries as a growth promoter for animals, was added to the list of examples under S1.2. • S-23 and YK-11 were listed as examples of SARMs in S1.2. S4. Hormone and Metabolic Modulators • S4.3 was updated to include antibodies of precursors of myostatin and as example, apitegromab was added. • The numbering was reformatted for clarity but there was no change in classification. 2 S5. Diuretics and Masking Agents • The introductory language of the section was revised to harmonize with other sections of the List. • Torasemide is added as an example of a diuretic and is already named in a WADA Technical Document (TD MRPL) and a WADA Technical Letter (TL24). • It was clarified that a Therapeutic Use Exemption is not required for topical ophthalmic administration of a carbonic anhydrase inhibitor (e.g. dorzolamide, brinzolamine) or for local administration of felypressin in dental anesthesia in conjunction with a threshold substance. 3 PROHIBITED METHODS M1. Manipulation of Blood and Blood Components • Voxelotor was added as an example, as it alters the ability of hemoglobin to release oxygen in the body, thereby enhancing arterial oxygen saturation. As a side effect, it increases serum erythropoietin, which has been shown to result in higher hemoglobin concentration in healthy individuals. 4 S6. Stimulants • 1,3-dimethylamylamine and 1,3 DMAA were added as alternative common names for 4-methylhexan-2-amine, while 1,4-dimethylamylamine and 1,4-DMAA were included as synonyms of 5-methylhexan-2-amine. • Solriamfetol was included in S6b due to its activity as a dopamine and norepinephrine reuptake inhibitor resulting in increases in brain levels of these neurotransmitters and consequent stimulant behavioral effects in preclinical species and in humans. • Tetryzoline was added as an imidazoline derivative under Exceptions. In addition, it is clarified that otic administration of imidazoline derivatives is not prohibited. S7. Narcotics SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES 1 a) Holgado D, Zandonai T, Zabala M, Hopker J, Perakakis P, Luque-Casado A, Ciria L, Guerra-Hernandez E, Sanabria D. Tramadol effects on physical performance and sustained attention during a 20-min indoor cycling time-trial: A randomised controlled trial. J Sci Med Sport. 2018 Jul;21(7):654-660. b) Mauger L, Thomas T, Smith S, Fennell C. (2022). Is tramadol a performance enhancing drug? A randomised controlled trial. British Association of Sport and Exercise Medicine Conference, 26-27 May 2022, Brighton, UK. https://basem.co.uk/wp-content/uploads/2022/08/Mauger_BASEM-Abstract.pdf https://www.wada-ama.org/en/resources/funded-scientific-research/tramadol-performance-enhancing-drug • Tramadol has been on the WADA Monitoring Program for some years. Monitoring data has indicated significant Use in sports including cycling, rugby and football. Tramadol abuse, with its dose-dependent risks of physical dependence, opiate addiction and overdoses in the general population, is of concern and has led to it being a controlled drug in many countries. Research studies funded by WADA1 have confirmed the potential for tramadol to enhance physical performance in sports. Consequently, as proposed in the draft 2023 Prohibited List circulated for consultation to stakeholders in May 2022, WADA’s Executive Committee approved, at its 23 September 2022 meeting, prohibiting tramadol during the In-Competition period. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of tramadol and the implementation of the new rule on 1 January 2024. A one-year delay in implementation will allow Athletes and medical personnel to better prepare for the change, Laboratories to update their procedures, and sports authorities to develop educational tools. S9. Glucocorticoids • It was clarified that otic administration of glucocorticoids is not prohibited. 5 P1. Beta-Blockers • At the request of the World Mini-Golf Federation (WMF), it was agreed to include mini- golf as a sport where beta-blockers are prohibited. The skills required for mini-golf are similar to others found in sports disciplines where beta-blockers are prohibited. • At the request of the World Under Water Federation (CMAS) beta-blockers will be prohibited Out-of-competition as well as In-competition in all subdisciplines of freediving, spearfishing and target shooting. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS 6 • Dermorphin and its analogs were added to detect patterns of use in sport In- competition. • GnRH analogs in females under 18 years were added to detect patterns of use in sport In- and Out-of-competition. • Hypoxen (polyhydroxyphenylene thiosulfonate sodium) was added to evaluate misuse in sport In- and Out-of-competition. * For further information on previous modifications and clarifications, please consult the Prohibited List Frequently Asked Questions at https://www.wada-ama.org/en/ prohibited-list#faq-anchor. MONITORING PROGRAM https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor 7 ADDENDUM Background • Following receipt of requests from a small number of stakeholders to remove (three national anti-doping organizations and one sports federation) or review (two anti-doping organizations) the prohibited In-competition status of cannabis from the Prohibited List, the WADA Executive Committee endorsed, during its meeting of September 2021, a recommendation of the WADA List Expert Advisory Group (LiEAG) to initiate a scientific review of the status of cannabis in 2022. • At present, the main psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), is prohibited In-competition and is reported as an Adverse Analytical Finding (AAF) by WADA-accredited laboratories when the urinary concentration- of carboxy- THC exceeds a threshold of 150 ng/mL with a Decision Limit of 180 ng/mL. This threshold was significantly increased in 2013 from 15 ng/mL in order to minimize the number of AAFs In-competition due to potential Use of THC Out-of-competition. This means that with the current threshold, Athletes most at risk of testing positive are those who have consumed significant quantities of THC close to In-competition Doping Control or are chronic users. • The 2021 World Anti-Doping Code (Code) incorporated the new Article 4.2.3 on Substances of Abuse for purposes of sanctioning under Code Article 10. Substances of Abuse are specifically identified on the Prohibited List because they are frequently abused in society outside of the context of sport. In this regard, the LiEAG identified THC as a Substance of Abuse for the 2021 Prohibited List, meaning that if the Athlete can establish that the THC use occurred Out-of-Competition and was unrelated to sport performance, the standard period of Ineligibility is three months, which may be reduced to one month if the Athlete satisfactorily completes an approved Substance of Abuse treatment program. While it is too early to evaluate the full impact of this new rule on sanctions for THC, preliminary data from 2021 indicates an increase in one- and three- month sanctions, suggesting that this provision is being applied. • Under the World Anti-Doping Program, the approach to cannabis on the Prohibited List has therefore evolved chronologically as follows: 2013: The urinary threshold increased from 15 ng/mL to 150 ng/mL with a Decision Limit of 180 ng/ ml. This significantly affected the number of AAFs, from an average of between 400-500 per annum in the years 2009-2012 to fewer than 100 in 2021. 2018: Cannabidiol (CBD) was removed from the Prohibited List, allowing Athletes who wish to use it to have access to the non-psychoactive component of cannabis. 2021: The inclusion of the Substance of Abuse provision in the Code significantly reduced the length of Ineligibility sanctions from a potential two (or even four) years previously to three (or even one) month(s) today for Athletes that can establish that the THC use occurred Out-of-Competition and was unrelated to sport performance. Under Article 9 of the Code, the Athlete will still lose their medal, prize and result. S8. Cannabinoids 8 The Review Process: • Since September 2021, the LiEAG, which is composed of external, international experts in pharmacology, forensic toxicology, drugs of abuse, analytical science, pharmacy, sports medicine, chemistry, endocrinology, internal medicine, regulatory affairs, peptides and growth factors and hematology embarked on a full de novo review of the status of delta9-tetrahydrocannabinol (THC) in sport. This extensive review focused on the three criteria set forth by Article 4.3 of the 2021 Code, namely: a. Medical or other scientific evidence, pharmacological effect or experience that the substance or method, alone or in combination with other substances or methods, has the potential to enhance or enhances sport performance; b. Medical or other scientific evidence, pharmacological effects or experience that the Use of the substance or method represents an actual or potential health risk to the Athlete; c. WADA’s determination that the Use of the substance or method contravenes the spirit of sport described in the introduction to the Code. • Under Code Article 4.3, a substance or method must meet at least two of these three criteria to be considered for inclusion in the Prohibited List. • Two subgroups of members of the LiEAG were formed, one to evaluate the effects of THC on performance enhancement (LiEAG-PE) and the other to assess the health risks (LiEAG-H). All existing scientific and medical publications related to these two topics were reviewed, as well as testimonials from Athletes who were/are cannabis users, available publicly, including in published surveys. • This scientific literature review was subsequently discussed with four world-renowned independent, external international experts (Ad-Hoc THC Expert Group) specialized in the pharmacology, toxicology, psychiatry and behavioral properties of THC and cannabinoids, to ensure that all relevant publications had been included and that all relevant scientific and medical aspects had been appropriately evaluated. The experts confirmed that the information review had been extensive and that all relevant data and aspects of the impact of THC on health and performance enhancement had been properly examined. • With respect to the Spirit of Sport criterion, the LiEAG Chair consulted with the WADA Ethics Expert Advisory Group (Ethics EAG). The Ethics EAG considered cannabis Use, at this time, to be against the Spirit of Sport across a cluster of areas listed in the Code, in particular: • Health • Excellence in Performance • Character and Education • Respect for rules and laws • Respect for self and other participants They also noted that: • Further research should be undertaken or supported in relation to Athletes’ perceptions of cannabis Use but also in relation to its potential (including placebo-induced) enhancing effects. These are areas of uncertainty owing to a lack of robust evidence. 9 Conclusions: After a thorough assessment and discussion under WADA Code Article 4.3, the LiEAG concluded that: a. There is compelling medical evidence that Use of THC is a risk for health, mainly neurological, that has a significant impact on the health of young individuals, a cohort which is overrepresented in Athletes. b. The current body of objective evidence does not support THC enhancement of physiological performance, while the potential for performance enhancement through neuropsychological effects still cannot be excluded. c. In consideration of the values encompassed by the Spirit of Sport as outlined by the Ethics EAG, and noting in particular that respect for self and other participants includes the safety of fellow-competitors, the Use of THC In-competition violates the Spirit of Sport. Based on these three criteria defined by the Code, on the scientific evidence available, THC meets the criteria to be included on the List. • Levels to trigger an Anti-Doping Rule Violation In-competition are such that they would be problematic on medical grounds for a competing Athlete, or indicative of a chronic habitual user. The present rule is not, as sometimes perceived or represented, an excessive incursion into private lifestyles. Nevertheless, and mindful of shifting public attitudes and laws in certain countries, the weight of evidence and argument, along with broad international restrictive regulatory laws and policies, supports the continuance of cannabis on the Prohibited List at this time. • The LiEAG Chair also consulted with the members of the WADA Athlete Committee to seek their opinions on the Use of cannabis in sport. The meeting reflected the range of opinions and views of the Athlete community. • In total, there were 10 consultative meetings held prior to the latest meeting of the LiEAG on 25-26 April 2022: • three by the LiEAG-PE • two by the LiEAG-H • one between the LiEAG Chair and the Athlete Committee Chair • one between the LiEAG Chair and the Athlete Committee • one between the LiEAG Chair and the Ethics EAG • one between the Ad-Hoc THC Expert Group and the LiEAG-PE • one between the Ad-Hoc THC Expert Group and the LiEAG-H 10 Future considerations: • These conclusions are based on the currently available scientific literature. From the extensive review conducted, it was evident that there is a lack of robust studies evaluating the performance enhancing effects of THC at both the physical and mental level. While anecdotal, self-reported evidence is available, further clinical studies are required to rigorously determine the neuropsychological impact of THC on performance. However, it is also acknowledged that such studies may be difficult to design. For example, it would require enrolling volunteers actively consuming THC, which in most countries is illegal; it would not be a truly blinded placebo study because the subject would feel the effect of THC leading to possible positive bias (to show it has performance enhancing effects and thus should be prohibited) or negative bias (to support exclusion from the List); it would be difficult to re-create the stress of a competition; and it is very unlikely that high level Athletes could be included as volunteers. Therefore, only those using cannabis and in regions where THC use is legal could be recruited, and in an Out-of-competition setting, with a risk of positive or negative bias. • As with all substances that are prohibited In-competition only, Athletes in regions where cannabis use is legal are advised to refrain from consuming cannabis for a number of days before the start of competition.